-
公开(公告)号：US20120070518A1
公开(公告)日：2012-03-22
申请号：US13239230
申请日：2011-09-21
IPC分类号： A61K36/886 , A61K36/00 , A61P17/06 , A61K31/404
CPC分类号： A61K31/404 , A61K9/0014 , A61K9/06 , A61K31/355 , A61K31/7056 , A61K36/886 , A61K45/06 , A61K2300/00
摘要： The present invention is directed to topical compositions and methods for topically treating psoriasis comprising meisoindigo as an active ingredient. The topical compositions preferably further comprise skin penetration enhancers, pharmaceutical surfactants and solubility enhancers, oil phase components, aqueous phase components, emulsifiers, moisturizers, antioxidants, vitamins, lubricants, herbal extracts, preservatives, and other ingredients. In addition to meisoindigo, the compositions may comprise other agents commonly used to topically treat psoriasis. The disclosed methods have been demonstrated to effectually treat moderate and severe forms of psoriasis to a degree similar to a potent corticosteroid without side effects. Preferably, the method involves topical application of the disclosed compositions to affected epidermal areas twice a day. In addition, the disclosed methods may be used in conjunction with other common therapies in the treatment of psoriasis.
摘要翻译： 本发明涉及用于局部治疗牛皮癣的局部组合物和方法，其包含异靛红作为活性成分。 局部组合物优选还包含皮肤渗透促进剂，药物表面活性剂和溶解度增强剂，油相组分，水相组分，乳化剂，保湿剂，抗氧化剂，维生素，润滑剂，草药提取物，防腐剂和其它成分。 除了异靛红之外，组合物可以包含通常用于局部治疗牛皮癣的其它试剂。 所公开的方法已被证明可有效地治疗中度和重度形式的牛皮癣至类似于强效皮质类固醇的程度而没有副作用。 优选地，该方法包括将所公开的组合物局部施用于受影响的表皮区域，每天两次。 此外，所公开的方法可以与治疗牛皮癣的其它常见疗法结合使用。
-
公开(公告)号：US07582670B2
公开(公告)日：2009-09-01
申请号：US11104422
申请日：2005-04-13
IPC分类号： A61K31/40 , A61K31/404 , A61K31/56
CPC分类号： A61K31/404 , A61K31/606 , A61K31/7056 , A61K45/00 , A61K45/06 , Y02A50/411 , A61K2300/00
摘要： The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.
摘要翻译： 本发明涉及治疗与促炎细胞因子表达相关的炎性相关疾病和/或降低抗炎细胞因子表达的药物组合物和方法。 该方法通常包括施用一种或多种选自异靛蓝，靛蓝，靛玉红或其衍生物的化合物，例如Meisoindigo和NATURA。 优选地，药物组合物包含一种或多种选自异靛蓝，靛蓝，靛玉红或其衍生物，抗炎剂和药学上可接受的载体的化合物。
-
公开(公告)号：US08563525B2
公开(公告)日：2013-10-22
申请号：US12972908
申请日：2010-12-20
CPC分类号： A61K31/404 , A61K31/7056
摘要： The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount less than sufficient to inhibit CDKs.
摘要翻译： 本发明涉及治疗与促炎细胞因子表达相关的炎性相关疾病和/或减少抗炎细胞因子表达的药物组合物和方法。 该方法通常包括一种或多种选自异靛，靛蓝，靛玉红或其衍生物的化合物，例如Meisoindigo和NATURA，其量小于足以抑制CDKs。
-
公开(公告)号：US08394847B2
公开(公告)日：2013-03-12
申请号：US12548083
申请日：2009-08-26
CPC分类号： A61K31/404 , A61K31/606 , A61K31/7056 , A61K45/00 , A61K45/06 , Y02A50/411 , A61K2300/00
摘要： The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.
-
公开(公告)号：US20090325895A1
公开(公告)日：2009-12-31
申请号：US12548083
申请日：2009-08-26
IPC分类号： A61K31/7056 , A61K31/404
CPC分类号： A61K31/404 , A61K31/606 , A61K31/7056 , A61K45/00 , A61K45/06 , Y02A50/411 , A61K2300/00
摘要： The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.
摘要翻译： 本发明涉及治疗与促炎细胞因子表达相关的炎性相关疾病和/或降低抗炎细胞因子表达的药物组合物和方法。 该方法通常包括施用一种或多种选自异靛蓝，靛蓝，靛玉红或其衍生物的化合物，例如Meisoindigo和NATURA。 优选地，药物组合物包含一种或多种选自异靛蓝，靛蓝，靛玉红或其衍生物，抗炎剂和药学上可接受的载体的化合物。
-
公开(公告)号：US20110160157A1
公开(公告)日：2011-06-30
申请号：US12972908
申请日：2010-12-20
IPC分类号： A61K31/7056 , A61K31/404 , A61P1/00 , A61P25/28 , A61P29/00 , A61P19/02
CPC分类号： A61K31/404 , A61K31/7056
摘要： The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount less than sufficient to inhibit CDKs.
摘要翻译： 本发明涉及治疗与促炎细胞因子表达相关的炎性相关疾病和/或降低抗炎细胞因子表达的药物组合物和方法。 该方法通常包括一种或多种选自异靛，靛蓝，靛玉红或其衍生物的化合物，例如Meisoindigo和NATURA，其量小于足以抑制CDKs。
-
公开(公告)号：US07855223B2
公开(公告)日：2010-12-21
申请号：US11494362
申请日：2006-07-26
申请人： Ruihuan Chen , Simon K. Mencher , Allen Tsao , Xiao Mei Liu , Longgui Wang
发明人： Ruihuan Chen , Simon K. Mencher , Allen Tsao , Xiao Mei Liu , Longgui Wang
IPC分类号： A61K31/40 , A61K31/405 , A61K31/56 , A61K31/19
CPC分类号： A61K31/404 , Y02A50/411 , Y02A50/463 , A61K2300/00
摘要： The present invention is directed to a method for treating inflammatory arthritis in a mammal. The method typically comprises administering to an animal a therapeutically effective amount of at least one compound selected from indigo, isoindigo, indirubin or derivatives thereof, such as NATURA-α or NATURA. The present invention is further directed to pharmaceutical compositions that include a therapeutically effective amount of at least one compound of the invention, an anti-inflammatory arthritis agent and a pharmaceutically acceptable carrier.
摘要翻译： 本发明涉及一种治疗哺乳动物炎症性关节炎的方法。 该方法通常包括向动物施用治疗有效量的至少一种选自靛蓝，异靛，靛玉红或其衍生物的化合物，例如NATURA-α或NATURA。 本发明进一步涉及药物组合物，其包含治疗有效量的至少一种本发明化合物，抗炎性关节炎药物和药学上可接受的载体。
-
公开(公告)号：US08748475B2
公开(公告)日：2014-06-10
申请号：US13197164
申请日：2011-08-03
申请人： Longgui Wang , Simon K. Mencher
发明人： Longgui Wang , Simon K. Mencher
IPC分类号： A61K31/404 , A61K31/573 , A61P13/12 , A61K39/395 , A61P19/04 , A61K31/7056 , A61K31/519
CPC分类号： A61K31/7056 , A61K31/404 , A61K31/519 , A61K31/573 , A61K45/06 , A61K2300/00
摘要： The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount sufficient to treat the lupus; preferably by modulating cytokine expression. Preferably the compound is in an amount less than sufficient to substantially inhibit cyclin dependent kinases.
摘要翻译： 本发明涉及治疗狼疮的组合物和方法。 方法通常包括以足以治疗狼疮的量施用一种或多种选自异靛蓝，靛蓝，靛玉红或其衍生物，例如Meisoindigo和NATURA的化合物的步骤; 优选通过调节细胞因子表达。 优选地，化合物的量小于足以基本上抑制细胞周期蛋白依赖性激酶。
-
公开(公告)号：US20120058121A1
公开(公告)日：2012-03-08
申请号：US13197164
申请日：2011-08-03
申请人： Longgui Wang , Simon K. Mencher
发明人： Longgui Wang , Simon K. Mencher
IPC分类号： A61K31/404 , A61K31/573 , A61P13/12 , A61K39/395 , A61P19/04 , A61K31/7056 , A61K31/519
CPC分类号： A61K31/7056 , A61K31/404 , A61K31/519 , A61K31/573 , A61K45/06 , A61K2300/00
摘要： The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount sufficient to treat the lupus; preferably by modulating cytokine expression. Preferably the compound is in an amount less than sufficient to substantially inhibit cyclin dependent kinases.
摘要翻译： 本发明涉及治疗狼疮的组合物和方法。 方法通常包括以足以治疗狼疮的量施用一种或多种选自异靛蓝，靛蓝，靛玉红或其衍生物，例如Meisoindigo和NATURA的化合物的步骤; 优选通过调节细胞因子表达。 优选地，化合物的量小于足以基本上抑制细胞周期蛋白依赖性激酶。
-
公开(公告)号：US20100098702A1
公开(公告)日：2010-04-22
申请号：US12561180
申请日：2009-09-16
IPC分类号： A61K39/395 , A61K31/404 , A61P35/04 , A61K31/573 , A61K38/00
CPC分类号： A61K31/404 , A61K9/0019 , A61K9/2004 , A61K31/337 , A61K31/573 , A61K31/7056 , A61K45/06 , A61K2300/00
摘要： The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-Δ3,3′-dihydroindole-2,2′ diketone; N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone; and N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells.
摘要翻译： 本发明涉及治疗前列腺癌的方法。 所述方法包括向有需要的患者施用至少一种选自N-甲基 - [1,3]二氢吲哚-2,2'二酮的化合物; N-1 - （＆bgr; -D-O-三乙酰基 - 木酮糖基） - ＆Dgr; 3,3'-二氢吲哚-2,2'二酮; 和N-1 - （＆bgr; -D-O-三乙酰基 - 木酮糖基）-N'-甲基 - ＆Dgr; 3,3'-二氢吲哚-2,2'二酮。 优选地，化合物的量足以抑制前列腺癌细胞的生长，侵袭和/或转移。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.031 秒)
